A Phase I/IIa Open Label, Nonrandomized, Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma.
Journal of clinical oncology（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要